Christies Care Ltd

Research

prnewswire | July 04, 2023

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x. Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich...

VIEWS AND ANALYSIS, PHARMA TECH

Anaqua and PatSnap | December 08, 2022

Anaqua, the leading provider of innovation and intellectual property management technology announced it is partnering with innovation intelligence platform PatSnap. The collaboration will deliver an enhanced IP management solution to provide Anaqua’s pharmaceutical industry clients with a more detailed and informed view of the market and competitive landscape for key use cases. The combined Anaqua AQX® Pharma and PatSnap Synapse solutions will help AQX Pharma clients further enhance co...

Pharmacy Market

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Pharma Tech

PRNewswire | May 17, 2023

Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony's unique polymeric material, "KIRAVIA™*2 Backbone." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which con...